Zoetis reported $9.52B of revenue over the trailing twelve months, +1.5% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $9.52B (to Q2 2026). Net income: $2.62B, trailing twelve months to Q2 2026. Free cash flow: $2.32B, trailing twelve months to Q2 2026. EPS: $6.07, trailing twelve months to Q2 2026.

ZTSZoetis

Healthcare

$74.80-49% 1Y

$74.80

$69.1152 weeks$145.76

ZTS as reported

Zoetis reported $9.52B of revenue over the trailing twelve months, +1.5% on the year before. 11 reported series are charted on this page, each one as filed.

$9.52B

Revenue, trailing twelve months · to Q2 2026 · +1.5% against the twelve months before

Net income: $2.62B
Net income · +0.96% year on year · trailing twelve months to Q2 2026
Free cash flow: $2.32B
Free cash flow · +2.1% year on year · trailing twelve months to Q2 2026
EPS: $6.07
EPS · +5.4% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ZTS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$9.52B	+1.5%	Q2 2026
Net income	$2.62B	+0.96%	Q2 2026
EPS	$6.07	+5.4%	Q2 2026
Gross margin	72%	n/a	Q2 2026
Operating margin	30%	n/a	Q4 2019 · 26 quarters behind
Net margin	27%	n/a	Q2 2026
ROE	73%	n/a	Q2 2026
ROA	17%	n/a	Q2 2026
ROIC	20%	n/a	Q4 2019 · 26 quarters behind
Free cash flow	$2.32B	+2.1%	Q2 2026
P/E	12.3	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.